@article{e74797004b3f480a901ac79d065ef003,
title = "Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases",
abstract = "Alemtuzumab is effective in relapsing remitting multiple sclerosis (RRMS). Serious adverse events have led to a renewed safety reassessment by the European Medicines Agency (EMA), leading to an approval under strict conditions. We report a RRMS patient experiencing diffuse alveolar hemorrhage (DAH) on day 4 of her first alemtuzumab cycle. In addition, we present an overview of the cases of alemtuzumab-induced DAH that were included in EMA's review procedure, additional well documented cases reported to the EMA and those cases reported in the literature. Combining these cases revealed striking similarities. Importantly, DAH was an early complication. All RRMS patients with known outcome showed complete recovery.",
keywords = "Adverse events, Alemtuzumab, Diffuse alveolar hemorrhage, Hemoptysis, Multiple sclerosis, Respiratory symptoms",
author = "Drop, {B. R. H.} and D. Zemel and Wokke, {B. H. A.} and {van Oosten}, {B. W.} and S. Dik and {Martins Jarnalo}, {C. O.} and Westerweel, {P. E.} and {de Beukelaar}, {J. W. K.}",
note = "Funding Information: The authors sincerely thank the patient for giving permission to report her case. In addition, we acknowledge doctor George Cheng (Department of Interventional Pulmonology, Bronchoscopy, and Pleural Disease, University of California, San Diego, USA) and professor Hilary J. Goldberg (Division of pulmonary and critical care medicine, Brigham and Women's Hospital, Boston, USA) for providing additional information on EMA case 2. Publisher Copyright: {\textcopyright} 2020 Elsevier B.V. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = jan,
day = "1",
doi = "10.1016/j.msard.2020.102614",
language = "English",
volume = "47",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
}